Skip to main content

Table 2 Characteristics and outcomes of patients

From: Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients

ID Age Gender Disease CART inj CART CRS ICANS Day 30 PET-scan Follow-up Outcome (Feb 19, 2021)
Grade Post infusion Grade Post infusion
UPN #1 65 F NHL GCB 3rd line January 27, 2020 axi-cel 2 D2 NA NA CR CR (M12) Alive
UPN #2 67 M NHL GCB 3rd line February 7, 2020 0 NA NA NA CR Relapse (M12) Alive
UPN #3 66 M NHL GCB 3rd line February 21, 2020 2 D2 4 D5 CR Relapse (M18) Alive
UPN #4 72 F NHL GCB 3rd line May 12, 2020 2 D12 2 D17 CR CR (M110) Alive
UPN #5 67 M NHL GCB 3rd line May 25, 2020 2 D5 2 D11 CR Relapse (M14) Dead (Oct 3, 2020)
UPN #6 65 M NHL GCB 4th line June 2, 2020 2 D1 3 D6 CR CR (M8) Alive
UPN #7 52 M NHL GCB 4th line June 12, 2020 2 D2 1–2 D14 PR CR (M8) Alive
UPN #8 70 F NHL GCB 3rd line July 20, 2020 1 D2 3 D5 Progression Refractory Dead (Oct 8, 2020)
UPN #9 54 F DLBCL (tFL), 3rd line May 13, 2019 0 NA 0 NA CR CR (M12) Alive (Jun 4, 2020)
UPN #10 69 F DLBCL NGC, 5th line July 11, 2019 2 D5 2 D6 CR CR (M12) Alive (Jul 9, 2020)
UPN #11 25 M B-ALL, 3rd line April 3, 2019 tisa-cel 0 NA 0 NA CR, negative MRD persisting B cell aplasia (M23), CD19low relapse (M23) Alive (Mar 5, 2021)
UPN #12 55 M DLBCL GC, 3rd line July 9, 2019 2 D3 0 NA PR CR (M18) Alive Jan 11, 2021
UPN #13 62 M DLBCL (tFL), 6th line June 4, 2019 0 NA 0 NA CR CR (M18) Alive (Mar 1, 2021)
UPN #14 23 M Phi + B-ALL, previous allograft, 2nd line June 12, 2019 1 D8 0 NA CR, negative MRD Loss of B cell aplasia (M6), molecular relapse (M6), CR with negative MRD (M19) after TKI treatment Alive (Jan 21, 2021)
UPN #15 56 M DLBCL (tFL), 4th line September 24, 2019 2 D4 1 D7 CR CR (M17) Alive (Feb 18, 2021)
UPN #16 15 M B-ALL, previous allograft, 4th line January 28, 2020 0 NA 0 NA CR, negative MRD CD19 + relapse (M6) Alive (Feb 18, 2021)
UPN #17 19 F B-ALL, 3rd line June 16, 2020 0 NA 0 NA CR, negative MRD CR with negative MRD (M1), Loss of B cell aplasia (M2), CR (M2), follow up in another center Alive (Aug 17, 2020)